Physician profile

Robert A May

Urology · Corpus Christi, TX

NPI 1699760710

$1,726.38

in general payments reported to CMS, 2019-2025

12 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$46.66

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astellas Pharma US INC $693.43 2019-2022
Neotract INC. $489.32 2019-2020
Myovant Sciences INC. $116.77 2021-2022
Endo Pharmaceuticals INC. $111.17 2019-2021
Teleflex LLC $99.93 2021
Boston Scientific Corporation $71.26 2021-2022
Abbvie INC. $46.66 2023
Janssen Biotech, INC. $39.89 2019-2021
Tolmar Pharmaceuticals, INC. $21.00 2019
Allergan, INC. $15.46 2019
Pfizer INC. $12.04 2020
Travere Therapeutics, INC. $9.45 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert A May

$1,726.38

in general payments reported 2019-2025

Years
2019-2023
Top company
Astellas Pharma US INC

https://glasscript.com/doctor/31179/robert-a-may

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.